EUR 13.6 Million Funding for Early Detection of Lynch Syndrome Cancers
Seppälä Lab has received EUR 13.6 million in funding to advance early detection of Lynch syndrome-associated cancers. Lynch syndrome is one of the most common hereditary cancer predisposition syndromes, significantly increasing lifetime risk of colorectal, endometrial, and other cancers.
This funding will support development of novel screening approaches and biomarkers aimed at earlier, more accurate detection — improving outcomes for Lynch syndrome carriers and their families.
